spironolactone has been researched along with cyclosporine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adorno, D; Casciani, CU; Cervelli, V; Cesarini, A; Filingeri, V; Iacona, A; Orsini, D; Rossetti, A | 1 |
| Bobadilla, NA; Feria, I; Gamba, G; García-Torres, R; González, MA; Juárez, P; López-Casillas, F; Pichardo, I; Ramírez, V; Uribe, N | 1 |
| Blanco, JA; Bobadilla, NA; Cruz, C; Derive, S; Gamba, G; Martínez de la Maza, L; Pérez-Rojas, JM | 1 |
| Blanco, JA; Bobadilla, NA; Bonventre, JV; Cruz, C; Gamba, G; Pérez-Rojas, J; Trujillo, J; Uribe, N; Vaidya, VS | 1 |
| Bie, P; Jensen, BL; Marcussen, N; Nielsen, FT; Skøtt, O | 1 |
| Miorin, LA; Sens, YA; Silva, FM | 1 |
| Bie, P; Hansen, PB; Jensen, BL; Marcussen, N; Nielsen, FT | 1 |
| Chen, YP; Li, M; Rui, HL; Sun, QL | 1 |
| Barbe, C; Bertocchio, JP; Jaisser, F; Lavaud, S; Nazeyrollas, P; Rieu, P; Toupance, O | 1 |
| Kream, RM; Ming, Y; Stefano, GB; Zhuang, Q | 1 |
1 review(s) available for spironolactone and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for spironolactone and cyclosporine
| Article | Year |
|---|---|
Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.
Topics: Adult; Aged; Cyclosporine; Drug Therapy, Combination; Eplerenone; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Renal Insufficiency; ROC Curve; Safety; Spironolactone; Transplant Recipients | 2016 |
19 other study(ies) available for spironolactone and cyclosporine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Reduced nephrotoxicity and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cyclosporine; Drug Therapy, Combination; Enalapril; Kidney Diseases; Liver Diseases; Male; Rats; Rats, Sprague-Dawley; Spironolactone | 1991 |
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Topics: Aldosterone; Animals; Chronic Disease; Collagen Type I; Collagen Type IV; Cyclosporine; Fibronectins; Immunosuppressive Agents; Kidney; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Wistar; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Benzamides; Clozapine; Cyclosporine; Diclofenac; Drug Eruptions; Female; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nimodipine; Paroxetine; Piperazines; Polyethylene Glycols; Prednisolone; Pyrimidines; Recombinant Proteins; Salicylamides; Spironolactone; Thioridazine; Vinblastine; Vinorelbine | 2003 |
Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity.
Topics: Aldosterone; Animals; Cyclosporine; Immunosuppressive Agents; Kidney Cortex; Male; Mineralocorticoid Receptor Antagonists; Organ Transplantation; Rats; Rats, Wistar; Receptors, Endothelin; Renin-Angiotensin System; RNA, Messenger; Spironolactone | 2005 |
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Topics: Animals; Apoptosis; Arterioles; Blood Pressure; Body Weight; Caspase 3; Cell Adhesion Molecules; Cyclosporine; Fibrosis; Immunosuppressive Agents; In Situ Nick-End Labeling; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA; Spironolactone; Transforming Growth Factor beta | 2007 |
Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
Topics: Animals; Blood Pressure; Cyclosporine; Disease Models, Animal; Eplerenone; Glomerular Filtration Rate; Kidney; Kidney Function Tests; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Regional Blood Flow; Spironolactone | 2008 |
The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A.
Topics: Animals; Creatinine; Cyclosporine; Disease Models, Animal; Disease Progression; Glomerular Filtration Rate; Kidney; Male; Mineralocorticoid Receptor Antagonists; Nephrotic Syndrome; Probability; Proteinuria; Random Allocation; Rats; Rats, Wistar; Reference Values; Risk Assessment; Sensitivity and Specificity; Spironolactone; Statistics, Nonparametric | 2008 |
The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.
Topics: Animals; Cyclosporine; Drug Interactions; Eplerenone; Fibrosis; Immunosuppressive Agents; Kidney; Longitudinal Studies; Male; Mineralocorticoid Receptor Antagonists; Nephritis, Interstitial; Rats; Rats, Sprague-Dawley; Spironolactone; Treatment Outcome | 2013 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Disease Models, Animal; Electrolytes; Eplerenone; Fibrosis; Kidney; Kidney Diseases; Male; Potassium; Rats, Sprague-Dawley; RNA, Messenger; Sodium; Spironolactone | 2015 |
Anti-Diabetogenic Properties of Mineralocorticoid Receptor Antagonists: Implications for Enhanced Safety and Efficacy of Post-Transplantation Pharmacotherapies.
Topics: Calcineurin; Calcineurin Inhibitors; Cyclosporine; Diabetes Complications; Diabetes Mellitus; Everolimus; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mineralocorticoid Receptor Antagonists; Sirolimus; Spironolactone; Tacrolimus; Transplantation Tolerance | 2019 |